Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 20, Issue 1, 2000, Pages 28-34

  Versiani, Marcio ^a   Amin, Mohammed ^b,d   Chouinard, Guy ^c  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Lakeshore General Hospital   (Canada)

^c CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^d SHIFA INTERNATIONAL HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; PLACEBO; REBOXETINE;

ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; MALE; MELANCHOLIA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; SEXUAL DYSFUNCTION; TREMOR; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AFFECT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES;

EID: 0033964747     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200002000-00006     Document Type: Article

References (32)

1. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WP, Docherty WR. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 1989;46:971-82.
2. Schatzberg AF. Treatment of severe depression with selective serotonin reuptake inhibitors. Depress Anxiety 1996-97;4: 182-9.
3. Kasper S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol 1997;17[suppl 1]:19S-28S.
4. World Health Organization. The ICD-10 classification of mental and behavioural disorders, clinical descriptors and diagnostic guideline. Geneva: World Health Organization, 1992.
5. Feighner JP, Cohn JB, Fabre LF Jr, Fieve RR, Mendels J, Shrivatava RK, Dunbar GC. A study comparing paroxetine, placebo, and imipramine in depressed patients. J Affect Disord 1993;28: 71-9.
6. Arminen SL, Ikonen U, Pulkkinen P, Leinonen E, Manlanen A, Koponen H, Kourula K, Ryyppo J, Korpela V, Lehtonen ML, Vartiainen H, Lehtinen V, Tamminen T, Manniche PM. A 12-week, double-blind, multi-centre study of paroxetine and imipramine in hospitalized depressed patients. Acta Psychiatr Scand 1994;89: 382-9.
7. Stuppaeck CH, Geretsegger C, Whitworth AB, Schubert H, Platz T, Konig P, Hinterhuber H, Fleischhaker WW. A multi-center, double-blind trial of paroxetine versus amitriptyline in depressed patients. J Clin Psychopharmacol 1994;14:241-6.
8. Ginestet E. Fluoxetine in endogenous depression and melancholia versus clomipramine. Int Clin Psychopharmacol 1989;4[suppl 1]:37-40.
9. Beasley CM Jr, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression: a multicenter trial. Ann Clin Psychiatry 1993;5:199-208.
10. Bowden CL, Schatzberg AF, Rosenbaum A, Contreras SA, Samson JA, Dessain E, Sayler M. Fluoxetine and desipramine m major depressive disorder. J Clin Psychopharmacol 1993;13: 305-11.
11. Ottevanger EA. The efficacy of fluvoxamine in patients with severe depression. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:731-40.
12. Danish University Antidepressant Group (DUAG). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-99.
13. Danish University Antidepressant Group (DUAG). Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl) 1986;90: 131-8.
14. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Clin Psychopharmacol 1994;8: 238-49.
15. Montgomery SA. Is there a role for a pure noradrenergic drug in the treatment of depression? Eur Neuropsychopharmacol 1997; 7[suppl 1]:S3-S9.
16. Leonard BE. Noradrenaline in basic models of depression. Eur Neuropsychopharmacol 1997;7[suppl 1]:S11-S16.
17. Riva M, Brunello N, Rovescalli AC, Galimberti R, Carfagna N, Carminati P, Pozzi O, Ricciardi S, Roncucci R, Rossi A, Racagni G. Effect of reboxetine, a new antidepressant drug, on the central nervous system: behavioural and biochemical studies. J Drug Dev 1989;1:243-53.
18. Wong EHF, Graveel CR, Smith MW. Pharmacological selectivity of reboxetine, a selective noradrenaline reuptake inhibitor (NRI). Poster presentation at the Annual Meeting of the American College of Neuropsychopharmacology, Hawaii, 1997.
19. Ban TA, Gaszner P, Aguglia E, Batista R, Castillo A, Lipcsey A, Macher JP, Torres-Ruiz A, Vergara L. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Hum Psychopharmacol 1998;13[suppl 1]:S29-S39.
20. Berzewski H, van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 1997;7[suppl 1]:S37-S47.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
22. Ban TA. CODE-DD: Composite Diagnostic Evaluation of Depressive Disorders. Brentwood, TN: JM Productions, 1989.
23. Zung WHK. A self-rating depression scale. Arch Gen Psychiatry 1965;12:53-70.
24. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, 1976.
25. Kraeplin E. Psychiatrie. 5th ed. Leipzig: Barth, 1896.
26. Lewis A. Melancholia: a clinical survey of depressive states. J Ment Sci 1934;80:277-378.
27. Leonhard K. The classification of endogenous psychoses. New York: Irvington, 1979.
28. Klein DF. Endogenomorphic depression: a conceptual and terminological revision. Arch Gen Psychiatry 1974;31:447-54.
29. Rush AJ, Weissenburger J. Melancholic symptom features. In: Widiger TA, Frances AJ, Pincus HJ, Ross R, First M, Davis WW, eds DSM-IV sourcebook. Washington, DC: American Psychiatric Association, 1996:193-238.
30. Kocsis JH, Croughan JL, Katz MM, Butler TP, Secunda S, Bowden CL, Davis JM. Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry 1990; 147:621-4.
31. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997;11:S9-S15.
32. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997;11:S33-S37.